Pharma News Intelligence February 12, 2024
On February 8th, CEOs from Bristol Myers Squibb, Johnson & Johnson, and Merck were grilled by US senators about high prescription drug prices.
In a heated Senate hearing on February 8th, the CEOs of Bristol Myers Squibb, Johnson & Johnson, and Merck faced rigorous questioning from various United States senators regarding the exorbitant prices of prescription drugs in the US. The testimony unfolded as a clash between the imperative of funding innovation and the growing outcry over affordability and accessibility.
Senator Bernie Sanders (I-VT), the chair of the Senate Health Committee, confronted the CEOs with stark figures.
“[Merck] made $52 million in total compensation in 2022 — will you commit to not accepting a single dollar more in compensation until...
Today's Sponsors
Today's Sponsor